Argenta Discovery Ltd. Announces Fourth Extension of Drug Discovery Collaboration With Genentech
Harlow, UK, 14 October 2013 – Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, today announces a three-year extension of its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). This is the fourth such extension since the agreement was first announced in December 2005. The agreement covers a portfolio of projects that utilizes Argenta's wide-ranging drug discovery expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Dr John Montana, Managing Director of Argenta, commented, “We are delighted that our long-standing and highly valued client, Genentech, has once again chosen to extend its collaboration with Argenta. We believe that this further extension is a testament both to the close working relationship that has been established between our companies over the years and the high level of success delivered by Argenta to Genentech in terms of pre-clinical candidate compounds, four of which are currently in clinical trials”.
About Argenta
Argenta is a fully-integrated drug discovery services provider and a trusted partner for many world-leading pharmaceutical and biotechnology companies including AstraZeneca, Genentech, Janssen and Zafgen.
Argenta combines a comprehensive range of discovery services with multiple disease area expertise including respiratory, oncology, pain and inflammatory disease, providing a compelling combination of scientific excellence, a full in vitro and in vivo pharmacology and DMPK capability, cutting edge medicinal chemistry thinking and cost-effectiveness.
Argenta provides fully-integrated and stand-alone services from target validation through to Development Candidate nomination and have built an Industry-leading track record of delivering development compounds, averaging over three development compounds per year.
Founded in 2000, Argenta currently employs over 160 scientists in the UK with an average of 17 years’ pharmaceutical drug discovery expertise. Argenta has delivered 40 development candidates in 13 years, and greater than 85% of the Company’s contract research is repeat business. More information at: www.argentadiscovery.com
CONTACTS
Media contact
Sarah Jeffery
Zyme Communications
Tel: +44 7771 730919
Email: sarah.jeffery@zymecommunications.com
Argenta
John Montana
Managing Director, Argenta
Tel. +44 1279 645645
Email: john.montana@glpg.com
Help employers find you! Check out all the jobs and post your resume.